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oziyahzakir@gmaAbstract Atorvastatin has low aqueous solubility resulting in low oral bioavailability (12%) and thus
presents a challenge in formulating a suitable dosage form. To improve the aqueous solubility, a solid
dispersion formulation of atorvastatin was prepared by lyophilization utilising skimmed milk as a
carrier. Six different formulations were prepared with varying ratios of drug and carrier and the
corresponding physical mixtures were also prepared. The formation of a solid dispersion formulation
was conﬁrmed by differential scanning calorimetry and X-ray diffraction studies. The optimum drug-
to-carrier ratio of 1:9 enhanced solubility nearly 33-fold as compared to pure drug. In vitro drug release
studies exhibited a cumulative release of 83.69% as compared to 22.7% for the pure drug.
Additionally, scanning electron microscopy studies suggested the conversion of crystalline atorvastatin
to an amorphous form. In a Triton-induced hyperlipidemia model, a 3-fold increase in the lipid
lowering potential was obtained with the reformulated drug as compared to pure drug. These results
suggest that solid dispersion of atorvastatin using skimmed milk as carrier is a promising approach for
oral delivery of atorvastatin.
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Drugs with poor aqueous solubility (less than 1 mg/mL1) are
an important problem for pharmaceutical scientists. Approxi-
mately 40% of the new chemical entities are poorly soluble.
Poor aqueous solubility hinders the in vivo efﬁcacy of the
drugs, causing low bioavailability, abnormal pharmacokinetic
proﬁle, and inter-subject, inter-species variation leading to
expensive and prolonged development2. There are many
approaches to increase solubility, such as use of surfactants,
complexation, polymorphism, salt formation, size reduction
and emulsiﬁcation3. The concept of solid dispersion (SD) is
one such approach which was introduced by Sekiguchi and
Obi4 in the 1960s as the dispersion of one or more active
ingredients in an inert carrier matrix at solid state. When the
SD is exposed to an aqueous environment the carrier dissolves
leaving the drug as ﬁne colloidal particles. This concept offers
numerous advantages, such as no use of toxic constituents, a
simple process, ﬂexibility in formulation, reduction of pre-
systemic metabolism, and improves the solubility and dissolu-
tion rate of the drug5. It is particularly advantageous for
Biopharmaceutical Classiﬁcation System class 2 drugs.
Atorvastatin is a member of the class of drugs known as
statins, used for lowering blood cholesterol level. It has very
good intestinal permeability and short half-life (Tmax, 1–2 h).
However, it has low oral bioavailability (12%) due to low
aqueous solubility (0.1 mg/mL), crystalline nature and hepatic
ﬁrst pass metabolism6. Poor performance of the drug leads to
administration in higher doses possibly leading to liver
abnormalities, rhabdomyolysis, arthralgia and kidney failure7.
To solve these problems, salt formation8 and inclusion com-
plexes with b-cyclodextrin9 has been tried. It has been reported
that solubility and bioavailability of crystalline atorvastatin
can be improved by developing a method simultaneously
reducing the particle size and converting the drug to an
amorphous state10. Solid dispersion technology utilizes these
principles for improved performance. Bobe et al.11 have
formulated an SD of atorvastatin using mannitol, PEG 4000
and PVP-K30. No attempt has been made to use skimmed
milk as the carrier in the formulation. Skimmed milk is
inexpensive, easily available, biodegradable, and does not
exhibit toxicity problems as experienced with PEG and
PVP12–14. Polymers as carriers also have limitations in enhan-
cing the solubility of poorly soluble drugs due to their high
viscosity. So the use of skimmed milk in the formulation of SD
of the drugs with limited aqueous solubility may be a potential
and cost effective way to overcome the problem.
In the present work, we developed a solid dispersion of
atorvastatin using skimmed milk. The skimmed milk is a
colloidal suspension of casein micelles, globular proteins and
lipoprotein particles. The principal casein fractions are a-s1,
a-s2, b-casein and k-casein. b-casein is amphiphilic and acts as a
detergent molecule with surfactant property. The milk also
contains whey proteins with principle fractions of b-lactoglo-
bulin, a-lactalbumin, bovine serum albumin and immunoglo-
bulins15. These molecules were found to be surface active with
superior solubility than caseins. The lyophilization procedure
was chosen because it provides protection against heat dena-
turation of protein molecules. The atorvastatin SD was eval-
uated for drug content, solubility and dissolution studies.
Varying ratios of drug and carrier were formulated and
evaluated. To deduce the possible effects of the carrier on thedrug, their physical mixtures (PM) were also formulated and
compared with SD and plain drug. This was followed by DSC,
XRD and SEM studies for conﬁrmation of formation of SD.
Finally in-vivo studies were carried out to elucidate the anti-
hyperlipidemic potential of SD with comparison to pure drug.2. Materials and methods
2.1. Materials
Atorvastatin was obtained as a gift sample from Micro Labs
Pvt. Ltd. Baddi (H.P., India). Triton WR 1339 (Tyloxapol)
was procured from Sigma Chemical Co, St Louis, MO, USA.
Double-toned milk (fat content 1.5%) was purchased from
Mother dairy (Punjab, India). All other solvents and reagents
were of analytical grade.
2.2. Preparation of skimmed milk16
Double-toned milk was stirred on a magnetic stirrer for 2–4 h
and extra fat in the milk was accumulated and removed. The
milk was then lyophilized for 72 h and the humidity of sample
was reduced to 3%. The obtained skimmed milk powder was
sieved through 250 mm mesh.
2.3. Preparation of SD
A SD containing atorvastatin with skimmed milk powder in
varying ratios (Table 1) were prepared by lyophilzation17. The
drug and carrier were prepared according to the speciﬁed drug-
to-carrier ratio. Atorvastatin was dissolved in methanol and the
carrier was put in a mortar. The drug solution was introduced
to the carrier with slow and continuous trituration until a
porous mass was formed. The mass was freeze-dried in a
lyophilizer at 40 1C. The solid mass was pulverized and
passed through sieve of 250 mm to get uniformly sized particles.
2.4. Preparation of PM
The PM was prepared by uniform mixing of drug and carrier in
the same ratios in a mortar. The solid mass was pulverized and
passed through sieve of 250 mm to get uniformly sized particles18.
2.5. Estimation of drug content19
The PM and SD equivalents to 40 mg of atorvastatin were
dissolved separately in 50 mL of 0.05 M phosphate buffer (pH
6.8). The solution was ﬁltered and further diluted so that the
absorbance fell within the range of standard curve. The
samples were ﬁltered through a 0.45 mm membrane ﬁlter and
the drug content was determined spectrophotometrically at
245 nm. The blank formulation was treated in the same
manner as the atorvastatin formulations and used as a blank
to minimize the interference of protein in the skimmed milk.
2.6. Saturation solubility studies20,21
Saturation solubility studies were conducted according to the
method reported by Hecq et al.21. Pure atorvastatin, PM and
SD formulations containing equivalent amounts of drug were
Table 1 Evaluation of different SD and PM formulations.
Code Ratio Atorvastatin (mg) Skimmed milk (mg) Drug contenta (%) Solubilitya (mg/mL)
at pH 6.8
SD 1 1:1 40 40 96.2270.54 0.43970.02
SD 2 1:3 40 120 97.5170.66 0.76670.03
SD 3 1:5 40 200 98.0270.73 1.08970.1
SD 4 1:7 40 280 99.6770.90 2.35470.15
SD 5 1:9 40 360 100.4470.98 4.15070.23
SD 6 1:10 40 400 99.1170.82 2.12370.10
PM 1 1:1 40 40 95.1670.45 0.30270.02
PM 2 1:3 40 120 96.4270.5 0.52670.04
PM 3 1:5 40 200 97.5670.84 0.78870.05
PM 4 1:7 40 280 98.0670.80 0.93070.06
PM 5 1:9 40 360 99.3070.85 1.11370.18
PM 6 1:10 40 400 102.4571.02 0.93470.05
SD, solid dispersion; PM, physical mixture.
aMean7SD, n¼3.
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phosphate (pH 6.8) buffer. The samples were placed on a
shaker, agitated for 48 h at 3770.5 1C until equilibrium was
achieved and the aliquots were ﬁltered through 0.45 mm ﬁlter.
The ﬁltered samples were diluted and assayed using a UV-
visible spectrophotometer against a blank prepared as
described previously (Electro lab, India).
2.7. Dissolution studies9
The in-vitro dissolution study was performed in a USP Type II
Dissolution rate test apparatus (Electro lab, India) using
900 mL of 0.05 M phosphate buffer (pH 6.8) at 3770.5 1C,
with gentle stirring for 30 min. Pure atorvastatin or its
equivalent of SD or PM was sprinkled into the dissolution
ﬂask. At predetermined time intervals, samples of the dissolu-
tion medium were withdrawn, ﬁltered through a millipore
membrane of 0.45 mm pore diameter and analysed spectro-
photometrically against a blank formulation.
2.8. Differential scanning calorimetry studies (DSC)22
DSC analysis of the skimmed milk, drug and its formulations was
carried out using a diamond calorimeter (Perkin–Elmer, Japan).
Samples (3–5 mg) were heated under a nitrogen atmosphere on an
aluminum pan at a rate of 10 1C/min under a dry nitrogen purge
of 40 mL/min over a temperature range of 20–200 1C.
2.9. X-ray powder diffraction analysis (XRD)23
X-ray diffraction patterns were traced on atorvastatin, SD, PM
and skimmed milk employing an X-ray diffractometer (X’pert
pro pan analytical, Netherland). The samples were analyzed
using Ni-ﬁltered Cu Ka radiation (l¼1.5418 A˚) under the
following condition: voltage 40 kV, current 40 mA, receiving
slit 0.2q inches, 2y range of 5–75 1C, scan rate 0.0401/s.
2.10. Scanning electron microscopic analysis (SEM)24
SEM analysis of drug, SD and PM was carried out using a
JSM-6100 scanning microscope (JEOL, Japan). Each sample wasmounted on stubs using conductive double-sided carbon tape and
spatter-coated with gold/palladium in a spatter coater for 90 s at
9 mA. The surface morphology of the samples was analyzed at an
acceleration voltage of 5 kV. Approximately 100 particles were
measured and mean diameter was determined.
2.11. In-vivo pharmacological study25,26
The anti-hyperlipidemic potential of the best optimized formula-
tions were tested using a Triton-induced hyperlipidemia model.
Male or female Wistar rats weighing 200–250 g were divided into
ﬁve groups (n¼6): Group I, normal control (0.9%, w/v sodium
chloride solution); Group II, Triton treated; Group III, Plain
atorvastatin; Group IV, PM 5; Group V, SD 5.
The study protocol was approved by the animal ethics
committee of Rayat Institute of Pharmacy. The animals were
starved for 18 h and then injected intravenously with 200 mg/kg
Triton WR 1339 (isooctyl-polyoxyethylenephenol, except
group I). At 45 min after injection atorvastatin or the SD
and PM formulations were administered p.o. (25 mg/kg) to
groups III, IV and V. Serum low density lipoprotein (LDL),
very low density lipoprotein (VLDL), cholesterol, triglycerides
and high density lipoprotein (HDL) levels were measured 24 h
after Triton injection. Animals were anesthetized with light
anesthetic ether and 1 mL blood was withdrawn from retro
orbital sinus. The blood was fractionated at 10,000 rpm for
10 min at 40 1C, and the serum was separated for analysis.
2.12. Statistical analysis
All the results are expressed as mean7SD and analyzed by
one way ANOVA followed by Tukey test. The value of
Po0.05 was considered to be signiﬁcant.3. Results and discussion
3.1. Drug content of formulations
Atorvastatin assay data for the SD and PM formulations are
given in Table 1. From the data it is clearly indicated that the
Ankush Choudhary et al.424drug content in the formulated solid dispersions (SD) and
physical mixtures (PM) was within the range of 75% of the
theoretical amount, indicating the method used for formula-
tion was suitable and reproducible in nature.3.2. In-vitro solubility and dissolution proﬁles
The primary goal of SD is to increase the solubility and
dissolution rate of a poorly water soluble drug. Pure atorvas-
tatin was found to have a saturation solubility of 0.127 mg/mL.
The solubility was enhanced 33-fold using the solid dispersion
technique (SD 5, Table 1). Similarly, the solubility of drug was
increased 9-fold in PM 5. Batches SD 5 and PM 5 gave the
highest solubility values of 4.15 mg/mL and 1.11 mg/mL,
respectively. The enhanced aqueous solubility of atorvastatin
observed with SD was possibly due to a reduction in particle
size and formation of an amorphous state, while in the case of
PM, the surface-active agents and amino acid content of the
milk may be responsible for better solubility. The hydrophilic
casein micelles entrap hydrophobic atorvastatin, thus improv-
ing the aqueous solubility27. The results proved that the carrier
skimmed milk was able to enhance the solubility of atorvas-
tatin in 0.05 M phosphate buffer (pH 6.8).
The dissolution proﬁles of the SD and PM formulations as
compared to plain atorvastatin are presented in Fig. 1.
Unaltered drug showed a dissolution of only 22.7% within
30 min. The dissolution of PM formulations ranged from
49.6% to 77.38% (Fig. 1A), whereas in case of SD it variedFigure 1 In-vitro dissolution release proﬁles of atorvastatin vs.
PM (A) and Atorvastatin vs. SD (B).from 51.2% to 83.69% (Fig. 1B). The results showed that the
percentage cumulative release from SD and PM was 2–3 times
higher than pure drug. The best dissolution was shown by
batches SD 5 and PM 5, 83.69% and 77.38%, respectively.
It is evident that the dissolution proﬁle continues to improve
with the increasing amounts of hydrophilic carrier matrix in
the formulations. However, beyond drug carrier ratio of 1:9,
the dissolution rates plunged. This may be because of higher
amounts of involved carrier which may take more time to
dissolve28. The increased solubility and dissolution exhibited
by SD can be explained by the formation of porous and ﬂuffy
particles by the lyophilization technique. This increases the
surface area and the surface free energy, thereby increasing the
dissolution rate29. The SD mixture showed higher dissolution
rate in comparison to PM perhaps because of the higher
energy metastable states of the components. Further, the
presence of carrier also prevents aggregation of ﬁne drug
particles, increasing dissolution of the drug. The wetting
property also has a signiﬁcant impact on the dissolution rate.
The surfactant property of the carrier decreases the interfacial
tension between the medium and the drug providing good
dissolution. Moreover, the presence of carrier inhibits the
crystal growth of the drug assisting in faster dissolution30.
In addition, the release mechanisms from various formulations
were studied. The data was found to best ﬁt the Higuchi
model31,32 (Table 2), indicating diffusion-restricted release33.
As skimmed milk mainly consists of globular and lipoprotein
particles which may interfere with the spectroscopic studies,
the respective blank formulations were treated in the same
manner as the test formulations.
From the in-vitro studies, it can be inferred that SD 5 and
PM 5 were best of all the formulations. The solubility and
dissolution rates exhibited by these formulations were max-
imal and higher than other formulations. Therefore, SD 5 and
PM 5 were selected for further studies.
3.3. Solid state studies of atorvastatin formulations
DSC has been shown to be a powerful tool in the character-
ization of solid state interactions between drug and skimmed
milk. The thermograms were analyzed by examining the peak
temperature and endothermic transition contours. The DSCTable 2 Order of drug release of various formulations
determined by the regression coefﬁcients.
Formulation Correlation regression coefﬁcient values (r2)
Zero order First order Higuchi model
PM 1 0.806 0.91 0.966
PM 2 0.413 0.461 0.729
PM 3 0.554 0.697 0.842
PM 4 0.453 0.577 0.763
PM 5 0.408 0.486 0.726
PM 6 0.442 0.363 0.762
SD 1 0.527 0.593 0.83
SD 2 0.379 0.4 0.68
SD 3 0.511 0.619 0.813
SD 4 0.398 0.47 0.719
SD 5 0.517 0.71 0.822
SD 6 0.462 0.474 0.772
Figure 3 X-ray powder diffractograms of atorvastatin (A),
skimmed milk (B), PM 5 (C) and SD 5(D).
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122.28 1C, due to loss of water or dehydration; the other at
160.64 1C corresponding to its melting point and thus indicating
crystalline nature (Fig. 2A). The skimmed milk exhibited a
broad endothermic peak at 81.93 1C in Fig. 2B depicting the
amorphous nature of skimmed milk. The thermogram of PM
5 depicts peaks at 86.56 1C, 139.04 1C and 166.66 1C which are
actually a combination of peaks of drug and skimmed milk
(Fig. 2C). On the other hand, the peak for the drug is absent in
SD 5 thermogram, suggesting the drug has interacted with the
carrier and has converted to amorphous form34 (Fig. 2D).
XRD patterns of atorvastatin, skimmed milk and the
formulations SD 5 and PM 5 are given in Fig. 3. The XRD
pattern of atorvastatin shows numerous sharp, narrow and
intense peaks at diffraction angles of 9.411, 10.181, 10.511,
11.91 and 19.121 reﬂecting its high crystallinity (Fig. 3A). The
spectrum of skimmed milk resembles a typical amorphous
material devoid of any characteristic peak (Fig. 3B). The XRD
pattern depicted by PM 5 reveals a decrease in the number of
peaks which probably represents decrease in crystallinity
(Fig. 3C). The patterns of SD 5 were shown to consist of
broader peaks with lower intensity, depicting conversion of
drug from crystalline to amorphous nature (Fig. 3D). On
comparison of the formulation patterns with that of pure
drug, it was observed that the number and intensity of peaks
were found to be less in samples and decreased in the
following order: Drug, PM 5, SD 5. Since it is generally stated
that if three consecutive relative intensity percentage values in
an XRD pattern decrease a decrease in crystallinity had
occurred in the samples, therefore, these observations can be
treated as conﬁrmation of the reduction in crystallinity and
thus phase transition35. As it is reported that amorphous
system is responsible for the enhancement in dissolution and
bioavailability36, less intense peaks in SD as compared to PM,
indicate an amorphous nature explaining the higher solubility
and dissolution proﬁles of SD as compared to PM. These
observations were in accordance with the DSC studies.
3.4. SEM
The microscopic investigations of atorvastatin, SD 5 and PM
5 were done by SEM analysis as shown in selected images.Figure 2 Differential scanning calorimetry thermograms of atoThe atorvastatin appeared as rod shaped crystals with smooth
surfaces and partially agglomerated in bundles (Fig. 4A). The
surface morphology of PM revealed mostly amorphous
particles (skimmed milk) and some crystals of drug, whereas
SD was in an amorphous state (Fig. 4B and C). Particle size
analysis by SEM showed samples of pure drug, PM and SD
have a mean diameter of about 5 mm, 4 mm and 1 mm,
respectively. The SEM analysis has conﬁrmed the results of
DSC and XRD studies and conﬁrmed the formation of solid
dispersion. Further, the conversion from crystalline to amor-
phous form is responsible for the reduction in particle sizes,
which is evident from the images. The reduced particle sizes
provided increased surface area and thus present an intimate
contact between hydrophilic carrier and drug27. This accounts
for enhanced in-vitro performance as observed for solid
dispersion formulations.rvastatin (A), skimmed milk (B), PM 5 (C) and SD 5 (D).
Figure 4 Scanning electron micrographs of atorvastatin (A), PM 5 (B) and SD 5(C).
Figure 5 Effect of atorvastatin formulations on cholesterol, HDL, LDL, triglycerides and VLDL in serum of control and experimental
rats. aPo0.05 vs. normal control (Group I); bPo0.05 vs. Triton induced (Group II); cPo0.05 vs. treatment with plain atorvastatin
(Group III); dPo0.05 vs. treatment with PM 5 (Group IV).
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Triton is a non-ionic surfactant that induces hyperlipidemia by
inhibiting peripheral lipoprotein lipase enzymes responsible
for the elimination of lipid particles from the body and leads
to transient elevation of lipid levels, which reach peaks at 18 h
to 24 h after administration of Triton37. In parallel to previous
reports, our data also demonstrate increases in the levels of
Low-density lipoprotein (LDL), cholesterol, triglycerides and
Very low-density lipoprotein (VLDL) after injection of Triton
in rats (Fig. 5). At the same time, Triton has also decreased the
serum High-density lipoprotein (HDL) levels. It is well-known
that HDL has a protective role in heart disease as it hastens
removal of cholesterol from peripheral tissues to the liver for
catabolism and excretion 38. The administration of various
formulations of atorvastatin was shown to affect the serum
lipid levels altered by Triton. For instance, PM 5 signiﬁcantly
reduced the levels of LDL by 41.4% and VLDL by 52.68%. It
also decreased the levels of serum triglycerides and cholesterol
by 35% and 38.8%, respectively. Better results were observed
on treatment with SD 5. It successfully reduced the levels of
LDL, VLDL, triglycerides and cholesterol by 75.5%, 61.7%,
90.9% and 62.6%, respectively. However, treatment with pure
drug did not show satisfactory results. It caused a reduction of
22.85% and 27.23% in LDL and VLDL levels, respectively,
and an inhibition of only 11.9% and 18% for cholesterol and
triglycerides, respectively. On the contrary, the levels of HDL
rose from 19 mg/dL to 34 mg/dL and 39 mg/dL by PM 5 and
SD 5 formulations, respectively. Again, the change in HDL
level by pure drug treatment was not signiﬁcant as it increased
the level by only 10 units to 29 mg/dL. On the basis of theabove results, it can be inferred that the effect of SD 5 and PM
5 on the serum lipid content was statistically signiﬁcant
(Po0.05) when compared with plain atorvastatin treatment.
The results are in accordance with previous reports which
suggested that atorvastatin reduces the levels of total choles-
terol, low density lipoprotein and triglycerides and augments
the level of HDL in blood 39. The anti-hyperlipidemia activity
exhibited by atorvastatin is because of its inhibitory activity
towards HMG-CoA reductase, the enzyme located in hepatic
tissue that produces mevalonate, an early rate-limiting step in
cholesterol biosynthesis40. Among the various formulations,
SD 5 was proved to be a more effective treatment with drastic
reduction in bad cholesterol and increase in HDL. In compar-
ison, the results shown by SD were 2-fold better than PM and
3 times better than pure drug treatment. An increase in HDL
levels and a reduced LDL level suggests the conversion of
LDL to HDL and clearance of lipids in the body. The higher
lipid-lowering activity of the SD 5 formulation can be
explained by the fact that the SD formulation resulted in
complete dissolution of atorvastatin, which increased absorp-
tion and thereby increased the bioavailability of the drug.
Hence, the activity of atorvastatin was signiﬁcantly increased
by using SD indicating better pharmacodynamic performance
of atorvastatin in comparison to pure drug or PM.4. Conclusions
In the present study we investigated the possibility of preparing
an SD of atorvastatin with skimmed milk by a lyophilization
technique. The DSC, XRD and SEM studies demonstrated the
An atorvastatin solid dispersion using skimmed milk for improved oral bioavailability 427formation of solid dispersions. The formulation was successful in
signiﬁcantly enhancing the solubility and dissolution rate of
atorvastatin. The formulation was found to be stable at ambient
temperature conditions. The pharmacological evaluation of the
formulation revealed signiﬁcant increase in its hypolipidemic
effect as compared to pure drug. Therefore, the present metho-
dology can be regarded as a novel and commercially feasible
technique for improving the in-vitro and in-vivo performance of
atorvastatin.Acknowledgments
The authors are grateful to Mr. Dinesh Dhull and Ms. Ramica
Sharma for providing valuable insights in the in-vivo studies.
The authors also acknowledge Punjab University, Chandigarh
and NIPER, Mohali for providing the necessary facilities to
carry out SEM, DSC and XRD studies. The authors are also
thankful to Micro Labs Pvt. Ltd for their generous help for
providing gift sample of atorvastatin.References
1. Verma S, Rawat A, Kaul M, Saini S. Solid dispersion: a strategy
for solubility enhancement. Int J Pharm Tech 2011;3:1062–99.
2. van de Waterbeemd H. The fundamental variables of the
biopharmaceutics classiﬁcation system (BCS): a commentary.
Eur J Pharm Sci 1998;7:1–3.
3. Choudhary A, Aggarwal G, Zakir F, Kumar V. Mini review:
journey of solid dispersion technique from bench to scale. Int Res
J Pharm 2011;2:46–51.
4. Sekiguchi K, Obi N. Studies on absorption of eutectic mixtures. I.
A comparison of behavior of eutectic mixtures of sulphathiazole
and that of ordinary sulphathiazole in man. Chem Pharm Bull
1961;9:866–72.
5. Bikiaris DN. Solid dispersions, part I: recent evolutions and future
opportunities in manufacturing methods for dissolution rate
enhancement of poorly water-soluble drugs. Expert Opin Drug
Deliv 2011;8:1501–19.
6. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of
atorvastatin and its hydroxy metabolites in rats and the effects of
concomitant rifampicin single doses: relevance of ﬁrst-pass effect
from hepatic uptake transporters, and intestinal and hepatic
metabolism. Drug Metab Dispos 2006;34:1175–81.
7. Shete G, Puri V, Kumar L, Bansal AK. Solid state characteriza-
tion of commercial crystalline and amorphous atorvastatin cal-
cium samples. AAPS Pharm Sci Tech 2010;11:598–609.
8. Ahjel SW, Lupuleasa D. Enhancement of solubility and dissolu-
tion rate of different forms of atorvastatin calcium in direct
compression tablet formulas. Farmacia 2009;3:291–300.
9. Palem CR, Patel S, Pokharkar VB. Solubility and stability
enhancement of atorvastatin by cyclodextrin complexation. PDA
J Pharm Sci Technol 2009;63:217–25.
10. Anwar M, Warsi MH, Mallick N, Akhter S, Gahoi S, Jain GK,
et al. Enhanced bioavailability of nano-sized chitosan–
atorvastatin conjugate after oral administration to rats. Eur J
Pharm Sci 2011;44:241–9.
11. Bobe KR, Subrahmanya CR, Suresh S, Gaikwad DT, Patil MD,
Khade TS, et al. Formulation and evaluation of solid dispersion of
atorvastatin with various carriers. Int J Compr Pharm 2011;1:1–6.
12. Anto´n Girone´s M, Roan Roan J, de la Hoz B, Sa´nchez Cano M.
Immediate allergic reactions by polyethylene glycol 4000: two
cases. Allergol Immunopathol (Madr) 2008;36:110–2.
13. Shelanski HA PVP K-30 14C single dose excretion study.
Unpublished report from the Industrial Toxicology Laboratories,United States of America. Submitted to the World Health
Organization by BASF 1953.
14. Shelanski MV Final two-year report of a chronic oral toxicity
study with PVP (K-30) in rats. Unpublished report from the
Industrial Biological Research and Testing Laboratories, United
States of America. Submitted to the World Health Organization
by BASF, 1957.
15. Sahin NO, Arslan H. Inclusion complex of prednisolone with
skimmed milk. Part I: physicochemical characterization. Yaku-
gaku Zasshi 2007;127:1255–61.
16. Topaloglu Y, Yener G, Kavalali G. Investigations of anti-
inﬂammatory activity of solid dispersion of indomethacin pre-
pared with skimmed milk. Acta Pharm Turcica 1998;40:13–6.
17. Chowdary KP, Rao SS. Investigation of dissolution enhancement
of itraconazole in superdisintegrants. Drug Dev Ind Pharm
2000;26:1217–20.
18. Vippagunta SR, Maul KA, Tallavajhala S, Grant DJ. Solid state
characterization of nifedipine solid dispersions. Int J Pharm
2002;236:111–23.
19. Venkates K, Arunkumar N, Verma PRP, Rani C. Preparation and
in-vitro characterization of valsartan solid dispersions using skimmed
milk powder as carrier. Int J Pharm Tech Res 2009;3:431–7.
20. van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P,
Augustijns P, et al. Physical stabilization of amorphous ketoco-
nazole in solid dispersions with polyvinylpyrrolidone K 25. Eur J
Pharm Sci 2001;12:261–9.
21. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparat-
ion and characterization of nanocrystals for solubility and dissolu-
tion rate enhancement of nifedipine. Int J Pharm 2005;299:167–77.
22. Topalog˘lu Y, Yener G, Go¨nu¨llu¨ U. Inclusion of ketoprofen with
skimmed milk by freeze-drying. Farmaco 1999;54:648–52.
23. Arunkumar N, Deecaraman M, Rani C, Mohanraj KP, Venkates K.
Preparation and solid state characterization of atorvastatin
nanosuspensions for enhanced solubility and dissolution. Int J
Pharm Tech Res 2009;1:1725–30.
24. Serajuddin AT. Solid dispersions of poorly-water soluble drugs:
early promises, subsequent problems, and recent breakthroughs.
J Pharm Sci 1999;88:1058–66.
25. Frantz Jr ID, Hinkelman BT. Acceleration of hepatic cholesterol
synthesis by triton WR-1339. J Exp Med 1955;101:225–32.
26. Kadu PJ, Kushare SS, Thacker DD, Gattani SG. Enhancement of
oral bioavailability of atorvastatin calcium by self-emulsifying drug
delivery systems (SEDDS). Pharm Dev Technol 2011;16:65–74.
27. Vijaya Kumar SG, Mishra DN. Preparation and evaluation of
solid dispersion of meloxicam with skimmed milk. Yakugaku
Zasshi 2006;126:93–7.
28. Ahire BR, Rane BR, Bakliwal SR, Pawar SP. Solubility enhance-
ment of poorly water soluble drug by solid dispersion techniques.
Int J Pharm Tech Res 2010;2:2007–15.
29. Simonelli AP, Mehta SC, Higuchi WI. Dissolution rates of high
energy polyvinylpyrrolidone (PVP)-sulfathiazole co-precipitates. J
Pharm Sci 1969;58:538–49.
30. Patel M, Tekade A, Gattani S, Surana S. Solubility enhancement
of lovastatin by modiﬁed locust bean gum using solid dispersion
techniques. AAPS Pharm Sci Tech 2008;9:1262–9.
31. Srikanth MV, Rao NS, Sunil SA, Ram BJ, Kolapalli VR.
Statistical design and evaluation of propranolol HCl gastric
ﬂoating tablet. Acta Pharm Sin B 2012;2:60–9.
32. Xu WJ, Li N, Gao CK. Preparation of controlled porosity
osmotic pump tablets for salvianolic acid and optimization of
the formulation using an artiﬁcial neural network method. Acta
Pharm Sin B 2011;1:64–70.
33. Jafar M, Dehghan MHG, Shareef A. Enhancement of dissolution
and anti inﬂammatory effect of meloxicam using solid dispersions.
Int J Appl Pharm 2010;2:22–7.
34. Feng BL, Li HW, Zhou MY, Lu W. Dispersion of daidzein with
polyvinylpyrrolidone effects on dissolution rate and bioavailabil-
ity. J Chin Med Mater 2011;34:605–10.
Ankush Choudhary et al.42835. Zidan AS, Rahman Z, Sayeed V, Raw A, Yu L, Khan MA.
Crystallinity evaluation of tacrolimus solid dispersions by chemo-
metric analysis. Int J Pharm 2012;423:341–50.
36. Newman A, Knipp G, Zograﬁ G. Assessing the performance
of amorphous solid dispersions. J Pharm Sci 2012;101:
1355–1377.
37. Biradar SS, Patil PA. Protective effect of Bauhinia Variegata
extracts on triton induced hyperlipidemia in rats. J Cell Tissue Res
2011;11:2785–8.
38. Chen TY, Pan BS. Ex vivo inhibitory effect on tilapia LDL
oxidation and hypolipidemia properties of Glycine tomentella rootextract. Comp Biochem Physiol A Mol Integr Physiol 2007;148:
189–95.
39. Bruemmer D, Yin F, Liu J, Kiyono T, Fleck E, van Herle A, et al.
Atorvastatin inhibits expression of minichromosome maintenance
proteins in vascular smooth muscle cells. Eur J Pharmacol
2003;462:15–23.
40. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat
MM, Szalai AJ, et al. Evidence for anti-inﬂammatory activity of
statins and PPAR alpha activators in human C-reactive protein
transgenic mice in-vivo and in cultured human hepatocytes
in-vitro. Blood 2004;103:4188–94.
